| Document |
Document Title |
|
WO/2022/170122A1 |
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, ...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/167819A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for t...
|
|
WO/2022/169997A1 |
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/167682A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/160637A1 |
A 3-aryl-6-aralkyl-1,4,5,6-tetrahydropyridazine compound, having the structure as shown in formula I. γ, δ-unsaturated N-aryl sulfonyl substituted hydrazone is subjected to a cyclization rearrangement reaction by means of a light and r...
|
|
WO/2022/161274A1 |
Disclosed in the present invention are a pyrimidine-2,4-diamine compound, a preparation method therefor and the use thereof, relating to the technical field of pharmaceutical chemistry. The pyrimidine-2,4-diamine compound of the present ...
|
|
WO/2022/161496A1 |
The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compound...
|
|
WO/2022/161166A1 |
A targeting chimeric compound, a pharmaceutical composition comprising same, a preparation method therefor and use thereof. The targeting chimeric compound is as represented by general formula (I), and each substituent in the general for...
|
|
WO/2022/163735A1 |
The present invention provides a compound that improves the performance of an organic EL element, an organic electroluminescent element having improved element performance, and an electronic device including such an organic electrolumine...
|
|
WO/2022/157499A1 |
The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
|
|
WO/2022/155981A1 |
Disclosed is the use of an N-heterocyclic carbene-based compounded nickel (II) complex in the synthesis of an α-benzyl benzofuran compound. In the present invention, an air-stable compounded nickel (II) complex Ni[P(OEt)3]{[R`NC(CH3)C(C...
|
|
WO/2022/152097A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/154282A1 |
The present specification relates to: a compound of chemical formula 1; and an organic light-emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first electrode and the se...
|
|
WO/2022/154283A1 |
The present specification relates to a compound and an organic light-emitting device comprising same.
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/147620A1 |
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs...
|
|
WO/2022/149476A1 |
A compound represented by formula (1) (wherein X1, X2, Y1 to Y3, L, *a, R1 to R9, R11 to R18, R21 to R27, and R31 to R34 are as defined in the specification). With this compound, an organic electroluminescent element having more improved...
|
|
WO/2022/149617A1 |
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...
|
|
WO/2022/148717A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2022/143501A1 |
An azaspirocyclic and polycyclic andrographolide compound with anti-tumor and antiviral activity, a preparation method therefor, a pharmaceutical composition comprising the azaspirocyclic and polycyclic andrographolide compound, and the ...
|
|
WO/2022/145408A1 |
The present invention provides compounds that have a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity, and pharmaceutically acceptable salts thereof, and also provides a serotonin 5-HT2A receptor antagonist and/or inv...
|
|
WO/2022/144002A1 |
Disclosed are a derivative of a 2,5-diketopiperazine compound, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed are a compound as represented by formula (I), a stereoiso...
|
|
WO/2022/147246A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2022/139304A1 |
The present invention relates to a novel quinazoline derivative compound that serves as an SOS1 inhibitor, and a use thereof, and more specifically to: a novel quinazoline derivative compound having inhibitory activity against SOS1 bindi...
|
|
WO/2022/139179A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/135072A1 |
Provided in the present invention are a coumarin compound, a preparation method therefor, and the use and a pharmaceutical composition thereof, belonging to the technical field of medicines. The coumarin compound provided in the present ...
|
|
WO/2022/134147A1 |
A compound and a method for preparing a substituted [5,6]cyclic-4(3H)-pyrimidone compound from same. The compound has the structure represented by formula II. The compound represented by formula II can be used to prepare a substituted [5...
|
|
WO/2022/134602A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic component, and an electronic device. The nitrogen-containing compound has a structure as shown in for...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/139228A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic material layer.
|
|
WO/2022/134613A1 |
The present application relates to the technical field of organic electroluminescence, and provides a nitrogen-containing compound, an electronic component comprising same, and an electronic apparatus. In the compound of the present appl...
|
|
WO/2022/139360A1 |
The present invention relates to a novel compound with excellent electron transport, light emission, and heat stability, and to an organic electroluminescent device that includes the compound in at least one organic material layer to hav...
|
|
WO/2022/140290A1 |
Provided herein are compounds of formula (A): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, Ry, and Rz are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2022/140309A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, A-oxides, and salts thereof, agricultural compositions containing them and their use as herbicides wherein R1, R2, R3, R4, R14, and X are as defined in the disclosure, A ...
|
|
WO/2022/133480A1 |
The present invention provides AHR agonists, composites thereof, and methods of using the same.
|
|
WO/2022/131887A1 |
The present invention relates to a novel compound with excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device that includes the compound in at least one organic materi...
|
|
WO/2022/127518A1 |
Disclosed by the present application are a nitrogen-containing organic compound and an electronic component and electronic apparatus using same; the nitrogen-containing organic compound has an adamantyl-substituted nitrogen-containing he...
|
|
WO/2022/129595A1 |
A material comprising an electron-accepting unit of formula (I): Ar is an aromatic ring; Ar1 is a substituted or unsubstituted 5- or 6-membered heteroaromatic ring containing N and C ring atoms; when Ar1 is a substituted or unsubstituted...
|
|
WO/2022/131697A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electronic element using same; and an electronic device thereof.
|
|
WO/2022/127199A1 |
The present invention relates to polycyclic compounds for inhibiting RNA helicase DHX33 and the use thereof. In particular, the present invention relates to a compound represented by formula VII or a pharmaceutically acceptable form ther...
|
|
WO/2022/129594A1 |
A material comprising an electron-accepting unit of formula (I). According to some embodiments, the present disclosure provides a material comprising an electron-accepting unit of formula (I) wherein Ar is a substituted or unsubstituted ...
|
|
WO/2022/131547A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/123039A1 |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain aldehyde dehydrogenase inhibitor compounds (also referred to herein as "ALDHI compounds"), that, ...
|
|
WO/2022/125610A1 |
Disclosed are compositions and methods related to the formulation and administration of vaccines to an individual in need thereof. In one aspect, the disclosed compositions and methods relate to improving the ability of a vaccine to prev...
|
|
WO/2022/124499A1 |
The present specification pertains to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2022/122987A1 |
The present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria, in particular Dirofilaria immitis.
|
|
WO/2022/124827A1 |
The present invention relates to a novel compound having excellent carrier transport ability, light-emitting ability, and thermal stability, and an organic electroluminescent device having improved characteristics in terms of luminescenc...
|
